Paul Feuerstadt, MD, and Louis Korman, MD, spoke with Becker’s about how a study published in The New England Journal of Medicine could change how the gastroenterology industry treats Clostridioides difficile.
The two physicians participated in the study, which showed that oral microbiome therapy SER-109 could be helpful in fighting recurrent C. diff.
Question: How do you think the findings from this study will affect the way the industry treats Clostridioides difficile?
Dr. Paul Feuerstadt: The SER-109 study was the first phase 3 clinical trial to publish their results in manuscript form considering a microbiota-based live biotherapeutic treatment. This is exciting because we believe the future of therapeutics for many diseases might involve this type of manipulation of the microbiota. In the case of C. difficile, we clearly understand the deficiency that SER-109 replaces.